頁籤選單縮合
題名 | 雙磷酸鹽用於骨質疏鬆症治療之探討=Bisphosphonates Treatment in Osteoporosis |
---|---|
作者 | 蕭力暢; 史明偉; 李怡靜; Hsiao, Li-chang; Shih, Ming-wei; Li, Yi-ching; |
期刊 | 藥學雜誌 |
出版日期 | 20101200 |
卷期 | 26:4=105 2010.12[民99.12] |
頁次 | 頁110-116 |
分類號 | 415.596 |
語文 | chi |
關鍵詞 | 雙磷酸鹽; 骨質疏鬆症; 骨折; Bisphosphonate; Osteoporosis; Fracture; |
中文摘要 | 骨質疏鬆症是老年人常見的內分泌疾病,根據世界衛生組織骨質疏鬆症,定義如表一,目前是全球第二大的重要流行病,預估亞洲地區到了 2050年的時候,因骨質疏鬆症而導致髖部骨折的人數,將高達 325萬人,將近占了全球的 45%。骨質疏鬆症和高血壓、高血脂等慢性疾病一樣,由於缺乏明顯症狀,因此需要提早預防,並積極接受藥物治療與追蹤。 在所有的骨質疏鬆症的治療藥物當中,又以雙磷酸鹽為最重要的使用藥物,其消耗金額約占全球骨質疏鬆症治療藥物的 73.2%之多。針對最近陸續核准上市的長效型雙磷酸鹽在骨質疏鬆症的治療,除有較佳的給藥方便性,特別是針對無法耐受口服雙磷酸鹽所造成的食道刺激及腸胃不適的患者更有其重要的考量點,然而在使用雙磷酸鹽的同時,每日仍需補充維生素 D及鈣。 |
英文摘要 | Osteoporosis is the secondary important disease around the world and is the more common endocrine disease in aging people. WHO predicts there will be exceed 3.25 million of people with hip fracture in Asia by the year 2050. Even though osteoporosis threatens people, however, it can be prevented and treated just like hypertension and hyperlipedemia. For the treatment of osteoporosis, bisphosphonates are the main class of drugs (shares ~73% of total medication) that inhibit osteoclastic activity and bone resorption. The more recent advance in bisphosphonates is the launch of IV bisphosphonates. The bisphosphonates are new choices especially for those who can not tolerate oral bisphosphonates due to esophageal irritation or GI discomfort. They may be a preferred option for some patients for dosing convenience; however, calcium and vitamin D supplements will still need to be taken daily. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。